Top ASX Cannabis Stocks of 2019

The Investing News Network presents a ranking of the three top ASX cannabis stocks during the full 2019 year.

Click here to read the latest top ASX cannabis stocks article.

The Australian cannabis market is offering investors a healthy dose of investment opportunities as the industry continues to expand in the country.

While the overall marijuana capital space has faced its fair share of volatility, which has affected Australian players as well, the emergent status of the sector in the country offers high upside in the long term for cannabis names attached to the Australian Securities Exchange (ASX).

Read along to find out about the top ASX cannabis stocks of 2019. All stock information and numbers were accurate as of December 16, 2019.

1. Ecofibre (ASX:EOF)

Year-to-date gain: 51.18 percent; current share price: AU$2.57

First on the list of top ASX cannabis stocks is Ecofibre, a biotech company that is working on the development of hemp-derived items for human and pet consumption in the US and Australia. Its hemp offerings include products for the health and wellness markets.

In 2019, the company completed a variety of developments that are critical to its production pipeline. One of the biggest announcements for the company this year was its approval to the NASDAQ International Designation program. Thanks to this admission, the company has gained more access to US investors with over-the-counter options.

Ecofibre CEO Eric Wang said that since the company’s profile in the US is increasing, the international designation gives investors an easier way to follow its activities.

2. Althea Group Holdings (ASX:AGH)

Year-to-date gain: 29.63 percent; current share price: AU$0.35

Althea Group Holdings takes the concept of medical cannabis a step further with its work as a pharmaceutical-grade cannabis supplier. In addition to offering relief through accessible medical cannabis, the company is implementing components of the plant in the research for advanced drugs.

The company has steadily increased its reach across Australia, with its patient count nearing 4,000 at the end of 2019. Patients who are counted are those who have been prescribed Althea products.

During an annual general meeting, Althea CEO Joshua Fegan told investors that the company holds enough capital to fund its future endeavors.

“Our goals for next year include reaching 10,000 patients in Australia, adding new products to our portfolio like we have just done with Althea CBD100 and continuing our expansion into the UK and Germany,” Fegan said.

3. Botanix Pharmaceuticals (ASX:BOT)

Year-to-date gain: 28.57 percent; current share price: AU$0.09

This pharmaceutical company has a focus on product development for dermatological conditions and offers treatments for acne, psoriasis, atopic dermatitis and other skin conditions in patients.

One of the company’s candidates, BTX 1503, progressed towards preparations for a Phase 3 clinical trial during 2019, which is a critical landmark.

The company received a boost for its business in the US after the US Drug Enforcement Administration told Purisys, a partner of Botanix, that synthetic cannabidiol (CBD) is not a controlled substance.

“This change in the regulation of synthetic CBD in the US will make a major difference to the speed of developing Botanic products and greatly reduces the risks and costs of clinical development,” Vince Ippolito, executive chairman and president of Botanix, said in a statement.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Rio Tinto reaches agreement with Turquoise Hill Resources on financing plan for Oyu Tolgoi

Rio Tinto has entered into a binding Heads of Agreement (HoA) with Turquoise Hill Resources (TRQ) for an updated funding plan (the “Funding Plan”) for the completion of the Oyu Tolgoi (OT) Underground Project in Mongolia. The Funding Plan addresses the estimated remaining known funding requirement of approximately $2.3 billion 1 , building on and replacing the arrangements established in the Memorandum of Understanding that Rio Tinto and TRQ previously entered into on 9 September, 2020.

Under the HoA, subject to securing approval by OT LLC and any required support from the Government of Mongolia, and subject to timing, availability, and terms and conditions being acceptable to both parties, Rio Tinto and TRQ will:

Keep reading... Show less

Rio Tinto Exploration and Calibre Mining Initiate 2021 Exploration Program Including 5,500 Metre Drilling Campaign Prioritizing Prospective Near-Surface Copper and Copper-Gold Mineralization

Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the “Company” or “Calibre”) is pleased to provide an update on the Borosi exploration project held under an earn-in option agreement between Rio Tinto Exploration (LSE:RIO) (“RTX”) (“Rio Tinto”) and Calibre. Calibre controls a 100% interest in the Borosi concessions located in the prolific Mining Triangle region of northeastern Nicaragua. RTX has the right to earn a 75% interest by spending US$45 million over eleven years in the project ( see Calibre news release dated February 24, 2020 ). The Borosi exploration program is being directed by RTX through a partnership agreement with Calibre as project operator.

Highlights

Keep reading... Show less

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study –

– Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis

Keep reading... Show less

Rio Tinto details $47 billion 2020 economic contribution, including $8.4 billion of taxes and royalties

Rio Tinto today released its 2020 Taxes paid: Our economic contribution report , which shows the company made a total direct economic contribution of $47 billion in the countries and communities where it operates, including $8.4 billion of taxes and royalties.

Despite the widespread challenges of COVID-19 in 2020, the contribution was up from the previous year, when Rio Tinto made a total direct economic contribution of $45.1 billion in the countries and communities where it operates, including $7.6 billion of taxes and royalties.

Keep reading... Show less

Top News

Related News